Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.
-
The CFH antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side effects.
-
The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.
-
A blog post on a modeling study from NCI researchers suggesting that individualized, risk-based selection of ever-smokers for lung cancer screening may prevent more lung cancer deaths compared with current screening recommendations.
-
A blog post on the FDA approval of the immunotherapy drug nivolumab for the treatment of some patients with Hodgkin lymphoma.
-
A blog post on a study showing that in patients with metastatic colorectal cancer, the location in the colon where the tumor originated appears to strongly influence how long patients live.
-
Cancer researchers are increasingly exploring how cancer risk is influenced by genetic predisposition to cancer and the effects of environmental exposures, and what this means for cancer prevention.
-
African Americans younger than age 50 had significantly worse 5-year survival rates at every stage of disease compared with young white and Hispanic patients, a new study shows.
-
“Moles to Melanoma: Recognizing the ABCDE Features” presents photos that show changes in individual pigmented lesions over time, and describes the different appearances of moles, dysplastic nevi, and melanomas.
-
NCI’s Dr. Robert Croyle discusses some of the issues related to cancer control faced by rural communities and how NCI is approaching this important problem.